Skip to main content
Print this page
Email this page link to a friend
Tweet this

John M. Pagel, MD, PhD, DSc

Medical Oncologist
Languages: English
Accepting New Patients
Professional Statement
Dr. Pagel is an international hematology expert with a world-class reputation for research and excellence in patient care. He is dedicated to individualized patient care that is based on mutual respect and trust. He is incredibly excited to be a part of the Swedish Cancer Institute. Dr. Pagel feels the work being done here is life-changing for patients and will deliver new advancements in cancer treatment for patients in the Pacific Northwest and beyond. Prior to joining Swedish, Dr. Pagel spent more than a decade as an associate member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center and associate professor in the Medical Oncology Division at the University of Washington. In his spare time Dr. Pagel enjoys skiing, boating, hiking and running in the Pacific Northwest.
Field of Study
Boston University School of Medicine
Medical School
University of California, San Francisco
Internal Medicine, Oncology
University of Washington/Fred Hutchinson Cancer Research Center, Senior Fellow, Dept. of Medicine, Division of Oncology
Medical Oncology
Professional Associations
Am. Society of Clinical Oncology, Am. Society for Blood and Marrow Transplantation, Am. Society of Hematology, Am. Assoc. for Cancer Research, Institute of Translational Health Sciences, Puget Sound Oncology Consortium
Personal Interests
Skiing, boating, running, hiking
Clinical Interests
  • amyloidosis
  • anemia
  • b12 deficiency anemia
  • blood cancer
  • cancer
  • cancer chemotherapy
  • cancer during pregnancy
  • cancer survivorship
  • egfr mutation
  • endocrine complications of cancer therapy
  • hellp syndrome
  • hematologic malignancies
  • hemochromatosis
  • hemolytic uremic syndrome
  • heparin induced thrombocytopenia
  • hereditary spherocytosis
  • histiocytosis
  • hypogammaglobulinemia
  • idiopathic thrombocytopenic purpura
  • iron deficiency anemia
  • leukemia
  • leukopenia
  • lymphoma
  • maternal hematologic disorders
  • multiple myeloma
  • myelodysplasia
  • myelodysplastic syndrome
  • neutropenia
  • pancytopenia
  • paroxysmal nocturnal hemoglobinuria
  • petechiae
  • plasma cell dyscrasia
  • polycythemia
  • pulmonary metastases
  • purpura
  • rh incompatibility
  • secondary polycythemia
  • splenomegaly
  • teratogen exposure
  • thalassemia
  • thrombocytopenia
  • thrombophilia
  • thrombotic thrombocytopenic purpura
  • unknown primary cancer

  Published/In Press

  1.  Mawad R, Lionberger J, Sandhu R, Gooley TA, Shannon-Dorcy K, Dean C, Scott B, Sandmaier BM,  O’Donnell P, Becker P, Petersdorf S, Hendrie P, Sorror ML, Holm N, Deeg J, Appelbaum FR, Estey EH., Pagel JM. Frequency of Allogeneic Hematopoietic Cell Transplantation among High-or Intermediate-Risk AML Patients in First Complete Remission. J Clin Oncol. In Press.
  2. Ostronoff  F, Othus M, Kantari H, Meshinshi S, Ravindi F, Hendrie PC, Faderl S, Becker PS, Cortes J, Pagel JM, Peters S, Godwin J, Willman C, Pierce S, List A, Sandhu V, Walter RB, Stirewalt DL, Appelbaum F, Chiatovich TJ, Esety EH. A Model for Prediction of FLT3-ITD and NPM1 (without FLT3-ITD) Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. Br J Haematol. In Press.
  3. Orozco JJ, Back T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM. Anti-CD45 Radioimmunotherapy Using 211At with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model.  Blood. 121(18):3759-3767, 2013.
  4. Cairo MS, Woessmann W, Pagel JM. Advances in Hematopoietic Stem Cell Transplantation (HSCT) in Childhood and Adolescent Lymphomas. Biol Blood Marrow Transplant. 19(1 Suppl):S38-S43, 2013. 
  5. Budde LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, Chen TL, Knudsen NL, Roden JE, Kammerer BE, Frayo SL, Warr TA, Boyd TE, Press OW, Gopal AK. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol. 161(2):183-191, 2013. 
  6. Timmerman JM, Byrd JC, Andorsky DJ, Yamada R, Kramer J, Muthusamy N, Hunder N, Pagel JM. A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders. Clinical Cancer Research. 18(20):5752-5760, 2012.
  7. Hattori N, Gopal AK, Shields AT, Fisher DR, Gooley T, Pagel JM, Press OW, Rajendran JG. 131I-Tositmomab Myeloablative Radioimmunotherapy for Non-Hodgkin Lymphoma: Radiation Dose to Testes. Nuclear Medicine Communications. 33(12):1225-1231, 2012.
  8. Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP, Sandmaier BM, Sorror M, Stirewalt DL, Wilson WA, Storb R, Appelbaum FR, Gooley T. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 120(7):1398-1408, 2012.
  9. Karp JE, Garrett-Mayer EL, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showell MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 97(11):1736-1742, 2012. 
  10. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 119(17):3940-3950, 2012.
  11. Park SI, Shenoi J, Frayo SL, Hamlin DK, Lin Y, Wilbur DS, Stayton PS, Orgun NN, Hylarides MD, Buchegger F, Kenoyer AL, Axtman A, Gopal AK, Green DJ, Pagel JM, Press OW. Pretargeted Radioimmunotherapy using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma. Clin Cancer Res. 17(23):7373-7382, 2011.   
  12. O’Donnell PV, Harrington E, Gooley TA, Pagel JM, Pereira S, Flowers ME, Hansen JA, Burroughs LM, Sandmaier BM, Storb RF, Luznik L, Jones RJ, Symonds HJ, Kasamon YL, Fuchs E. Cyclophosphamide-Induced Tolerance Following Bone Marrow Transplantation from Haploidentical Donors.  Haematologica (Extra 1)
  13. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with High Dose Cytarabine Granulocyte Colony-Stimulating Factor (G-CSF) Priming for Relapsed and Refractory Acute Myeloid Leukemia. Br J Haematol. 155(2):182-189, 2011.
  14. Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger W, Holmberg LA, Shustov AR, Maloney DG, Gopal AK. Mantle Cell International Prognostic Index but not Pretransplantation Induction Regimen Predicts Survival for Patients with Mantle-Cell Lymphoma receiving High Dose Therapy and Autologous Stem-Cell Transplantation. J Clin Oncol. 29(22):3023-3029, 2011.  
  15. Pagel JM, Kenoyer AL, B�ck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozoco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Anti-CD45 Pretargeted Radioimmunotherapy using Bismuth-213: High Rates  of Complete Remission and Long-Term Survival in a Mouse Myeloid Leukemia Xenograft Model. Blood. 118(3):703-711, 2011.  
  16. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, Matesan MC, Storb RF, Press OW. 90Y-ibritumomab Tiuxetan, Fludarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Patients with Persistent High-Risk B-Cell Lymphoma. Blood. 118(4):1132-1139, 2011.  
  17. Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH, Shustov AR, Flowers MED, O’Donnell P, Sandmaier BM, Storb RF, Gopal AK. Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 17(10):1537-1545, 2011.  
  18. Walter RB, Gooley T, Loken M, Estey E, Becker PS, Salter AI, Lansverk E, Appelbaum FR, Pagel JM. Impact of Pre-Transplant Minimal Residual Disease on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia in First Complete Remission. J Clin Oncol. 29(9):1190-1197, 2011.  
  19. Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, Loeb KR, Martin PJ, Pagel JM, Radich JP, Sandmaier BM, Warren EH, Storb RF, Appelbaum FR, Deeg HJ. Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival is Determined by Karyotype and Comorbidities. Biol Blood Marrow Transplant. 17(6):908-915, 2011.
  20. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, B�ck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Conventional and Pretargeted Radioimmunotherapy Using Bismuth-213 to Target and Treat Non-Hodgkin Lymphomas Expressing CD20: A Preclinical Model for Optimal Consolidation Therapy to Eradicate Minimal Residual Disease. Blood. 116(20):4231-4239, 2010.
  21. Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ. Conditioning with Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 17(3):341-350, 2011.  
  22. Wilbur DS, Park SI, Chyan MK, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur S, Buchegger F, Pantelias A, Pagel JM, Press OW. Design and Synthesis of Bis-Biotin-Containing Reagents for Application to Monoclonal Antibody-Based Pretargeting Using Streptavidin Mutants. Bioconjug Chem. 21(7):1225-1238, 2010.  
  23. Alyea EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepiorka D, Riddell S, Sadelin M, Young JW, Giralt S, Bishop M.  NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention  of Relapse Following Allogeneic Cell Transplantation for Hematological Malignancies. Biol Blood Marrow Transplant. Biol Blood Marrow Transplant. 16(8):1037-1069, 2010.
  24. Gopal AK, Press OW, Shuster AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE, Smith JC, Pagel JM.  Efficacy and Safety of Gemcitabine, Carboplatin, Dexamethasone, and Rituximab in Patients with Relapsed/Refractory Lynmphoma: A Prospective Multi-Center Phase II Study by Puget Sound Oncology Consortium (PSOC). Leuk Lymphoma. 51(8):1523-1529, 2010.  
  25. *Walter RB, *Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE, Hansen JA, Salter AI, Lansverk E, Stewart M, O’Donnell PV, Appelbaum FR. Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission. Leukemia. 24(7):1276-1282, 2010. *Shared first author.
  26. Woolfrey AE, Lee SJ, Gooley T, Malkki M, Martin PJ, Pagel JM, Hansen JA, Petersdorf EW. HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category. Biol Blood Marrow Transplant. 16(10):1382-1387, 2010.  
  27. Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ, Storb R, Press OW, Appelbaum FR. Allogeneic Hematopoietic Cell Transplantation after Conditioning with 131I-anti-CD45 Antibody Plus Fludarabine and Low-Dose Total Body Irradiation for Elderly Patients with Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. Blood. 114(27):5444-5453, 2009. 
  28. Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Wilbur DS, Hamlin DK, Gopal AK, Park SI, Press OW. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in non-human primates. Blood. 114(6):1226-1235, 2009.  
  29. Wilbur DS, Thakar MS, Hamlin DK, Santos EB, Chyan M, Nakamae H, Pagel JM, Press OW, Sandmaier BM.  Reagents for Astatination of Biomolecules. Comparison of Maleimido-closo-Decaborate(2-) and meta-Benzoate Conjugates for Labeling anti-CD45 Antibodies with [211At]Astatine. Bioconjug Chem. 20(10):1983-1991, 2009.  
  30. Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW. I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin Lymphoma. Blood. 113(23):5905-5910, 2009.  
  31. Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R, Sandmaier BM. Biodistributions, Myelosuppression and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211. Cancer Res. 69(6):2408-2415, 2009.  
  32. Pagel JM, Orgun N, Hamlin DK, Wilbur S, Gooley T, Gopal AK, Park SI, Green D, Lin Y, Press OW. A Comparative Analysis of Conventional and Pretargeted Radioimmunotherapy of B-Cell Lymphomas by Targeting CD20, CD22, and HLA-DR Singly and in Combinations. Blood. 113(20):4903-4913, 2009.   
  33. Pagel JM, Matthews DC, Kenoyer A, Hamlin D, Wilbur DS, Fisher D, Gopal AK, Lin Y , Saganic L, Appelbaum FR, Press OW.  Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia. Cancer Res. 69(1):185-192, 2009.  
  34. Gopal AK, Metcalfe TL, Gooley TA, Press OW, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Maloney DG. High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin lymphoma: the Seattle experience.  Cancer. 113(6):1344-1350, 2008.  
  35. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, James S, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW.  Adoptive Immunotherapy for Non-Hodgkin Lymphoma Using Genetically Modified Autologous CD20-Specific T Cells.  Blood. 112(6):2261-2271, 2008.
  36. Gopal AK, Press OW, Wilbur DS, Maloney D, Pagel JM. Rituximab blocks binding of radio-labeled anti-CD20 antibodies (Ab) but not radio-labeled anti-CD45-Ab. Blood. 112(3):830-835, 2008.  
  37. Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur DS, Nilsson R, Sandberg B, Press OW. Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies. Cancer Biother Radiopharm. 23(2):181-191, 2008.
  38. Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH, Pagel JM, Holmberg L, Bensinger W, Press OW.  Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma. 29:1-12, 2008.  
  39. Walter RB, Boyle KM, Appelbaum FR, Bernstein ID, Pagel JM. Simultaneously Targeting CD45 Significantly Increases Cytotoxicity of the Anti-CD33 Immunoconjugate, Gemtuzumab Ozogamicin, Against Acute Myeloid Leukemia (AML) Cells and Improves Survival of Mice Bearing Human AML Xenografts.  Blood. 111(9):4813-4816, 2008.  
  40. Pagel JM, Hedin N, Drouet L, Wood B, Pantelias A, Lin Y, Hamlin DK, Wilbur DS, Gopal AK, Green D, Appelbaum FR, Press OW. Eradication of Disseminated Leukemia in a Syngeneic Murine Leukemia Model Using Pretargeted Anti-CD45 Radioimmunotherapy. Blood. 111(4):2261-2268, 2008.  
  41. Pham RN, Gooley TA, Keeney GE, Press OW, Pagel JM, Greisman HA, Bensinger WI, Holmberg LA, Petersdorf SH, Maloney DG Gopal AK.  The Impact of Histologic Grade on the Outcome of High-Dose Therapy and Autologous Stem Cell Transplantation for Follicular Lymphoma. Bone Marrow Transplant. 40(11):1039-1044, 2007.
  42. Keeney GE, Gooley TA, Press OW, Pagel JM, Petersdorf SH, Maloney DG, Gopal AK.  The Pretransplant Follicular Lymphoma International Prognostic Index is Associated with Survival of Follicular Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.  Leuk Lymphoma. 48(10):1961-1967, 2007.
  43. Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur DS, Gopal A, Hamlin DK, Press OW. Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res. 13(18):5598s-5603s, 2007.
  44. Pagel JM, Lionberger J, Gopal AK, Sabath DE, Loeb K. Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Am J Hematol. 82(12):1121-1122, 2007.
  45. Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW. Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-cell Lymphomas. Cancer Res. 67(12):5921-5298, 2007.
  46. Ying SX, Seal S, Abbassi N, Kiem HP, Pagel JM, Gopal AK, Deeg J.  Differential Effects of Bexarotene on Intrinsic and Extrinsic Pathways in TRAIL-Induced Apoptosis in Myeloid Leukemia Cell Lines. Leuk Lymphoma. 48(5):1003-1014, 2007.
  47. Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF Appelbaum FR, Press OW. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 25(11):1396-1402, 2007.
  48. *Pantelias A, *Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur DS, Stone D, Axworthy D, Gopal AK, Press OW. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22 and DR molecules on human B cell lymphomas. Blood. 109(11):4980-4987, 2007.  *Shared first author
  49. Gopal AK, Pagel JM, Rajendran JG, Maloney DG, Appelbaum FR, Sorror ML, Sandmaier BM, Storb R, Press OW.  Improving the Efficacy of Reduced-Intensity Allogeneic Transplantation for Lymphoma Using Radioimmunotherapy. Biol. Blood Marrow Transplant. 12(7):697-702, 2006.
  50. *Lin Y, *Pagel JM, Axworthy D, Hedin N, Press OW.  A Genetically Engineered scFv4SA Fusion Protein for Pretargeted Radioimmunotherapy.  Cancer Res. 66(7):3884-3892, 2006. *Shared first author
  51. Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, Hamlin DK, Wilbur DS, Press OW.  Comparison of a Tetravalent Single-Chain Antibody-Streptavidin Fusion Protein and an Antibody-Streptavidin Chemical Conjugate for Pretargeted Anti-CD20 Radioimmunotherapy of B-cell Lymphomas.  Blood. 108(1):328-336, 2006.
  52. Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, Ruffner K, Nemecek ER, Sickle E, Durack L, Carreras J, Horowitz MM, Press OW, Gopal AK, Martin PJ, Bernstein ID, Matthews DC.  131I-anti-CD45 Antibody Plus Busulfan and Cyclophosphamide before Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia in First Remission. Blood. 107(5):2184-2191, 2006.
  53. Kerbauy DMB, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM, Myerson D, Appelbaum FR, Storb R, Deeg HJ. Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia.  Biol. Blood Marrow Transplant. 11(9):713-720, 2005.
  54. Pagel JM, Laugen C, Hedin N, deVries P, Coon M, Bonham L, Singer J, Press OW.  I Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.  Clin Cancer Res. 11(13):4857-4866, 2005.
  55. Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, Storb R, Gopal AK.  Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older.  J Clin Oncol. 23(15):3439-3446, 2005.
  56. Nemecek ER, Hamlin DK, Fisher DR, Krohn KA, Pagel JM, Appelbaum FR, Press OW, Matthews DC. Biodistribution of 90Y-labeled anti-CD45 antibody in a nonhuman primate model.  Clin Cancer Res 11:787-794, 2005.
  57. *Gopal AK, *Pagel JM, Hedin N, Press OW.  Fenretinide Enhances Rituximab-Induced Cytotoxicity against B Cell Lymphoma Xenografts through a Caspase-Dependent Mechanism.  Blood. 103(9):3516-3520, 2004.   *Shared first author
  58. Pagel JM, Kerr KM, Kirkwood KS, Welton M, Abbo M, Hricak H, Pantilat SZ.  Retrospective Analysis of a Guideline for the Evaluation of Older Patients with Non-Traumatic Abdominal Pain Presenting to the Emergency Department.  J Clin Outcomes Manage. 10(11):1-7, 2003.
  59. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Wilbur DS, Matthews DC, Press, OW. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.  Blood. 101(8):2340-2348, 2003.
  60. Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallet RW, Stayton PS, Press, OW. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.   J Nucl Med. 44:437-445, 2003.
  61. Giese K, Pagel J, Grosschedl R.  Functional Analysis of DNA Bending and Unwinding by the High Mobility Group Domain of LEF-1.  Proc Natl Acad Sci USA. 94(24):12845-12850, 1997.
  62. Giese K, Pagel J, Grosschedl R.  Distinct DNA-binding Properties of the High Mobility Group Domain of Murine and Human SRY Sex-Determining Factors.  Proc Natl Acad Sci USA. 91:3368-3372, 1994.
  63. Pagel JM, Winkelman JW, Adams CA, Hatfield GW.  DNA topology-mediated regulation of transcription initiation from the tandem promoters of the ilvGMEDA operon of Escherichia coli.  J Mol Biol. 224:919-935, 1992.
  64. Pagel JM, Hatfield GW.  Integration Host Factor-mediated Expression of the ilvGMEDA Operon of Escherichia coli.  J Biol Chem. 266:1985-1996, 1991.
 Book Chapters/Reviews/Other Publications

  1. Pagel JM, Gopal AK. Radioimmunotherapy and Hematopoietic Cell Transplantation. In: Appelbaum FR, Negrin R, Antin J, and Forman SJ (Eds). Hematopoietic Cell Transplantation. 5th edition. Blackwell Scientific. Invited Book Chapter. In Press.
  2. Mawad R, Lionberger JM, Pagel JM. Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports 8(2):132-140, 2013.
  3. Orozco J, Zeller J, Pagel JM.  Radioactive Isotopes Combined with Antibodies Directed at CD45 for Conditioning Prior to Allogeneic Transplant in AML.  Therapeutic Advances in Hematology, Invited Review.  Therapeutic Advances in Hematology 3(1):5-16, 2012.
  4. Gutman JA, Smith KM, Pagel JM. Chronic Lymphocytic Leukemia (CLL) (chapter 3). In: Estey EH & Appelbaum FR (Eds). Leukemia and Related Disorders: Integrated Treatment Approaches. Humana Press. 2012; pp. 67-96. Invited Book Chapter.
  5. Walter RB, Pagel JM. Targeted Radionuclide Therapy for Leukemia (chapter 34). In: Speed TW (Ed). Targeted Radionuclide Therapy. 1st edition. Lippincott Williams & Wilkins. 2011; pp. 411-457.
  6. Walter RB, Press OW, Pagel JM. Pretargeted Radioimmunotherapy for Hematologic and Other Malignancies. Cancer Biotherapy & Radiopharmaceuticals 25(2): 125-142, 2012.
  7. Shenoi J, Gopal AK, Press OW, Pagel JM.  Novel Radioimmunotherapeutic Approaches for Allogeneic Hematopoietic Cell Transplantation - Current Trends to Reduce Relapse.  Invited Review.  Current Opinion in Oncology 22(2):143-149, 2010.  
  8. Pagel JM, Boerman O, Breitz HB, Meredith R. “Targeted Radionuclide Therapy of Cancer”.  Chapter 13 in the 5th Edition of Principles of Cancer Biotherapy, Oldham RK, Dillman RO, (eds.) Published August 2009.
  9. Pagel JM. Radioimmunotherapeutic approaches for leukemia: the past, present and future. Cytotherapy 10(1):13-20, 2008.
  10. Pagel JM, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. The Use of Radioimmunoconjugates in Stem Cell Transplantation. Bone Marrow Transplantation  29(10):807, 2002.
  11. Grosschedl R, Giese K, Pagel J. HMG Domain Proteins: Architectural Elements in the Assembly of Nucleoprotein Structures.  Trends in Genetics 10:94-100, 1994.
 Submitted or In Preparation
  1. Cassady RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK. Specific features identify patients with relapsed/refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Submitted.
  2. Estey E, Veatch JR, Sandhu V, Becker PS, Pagel JM, Appelbaum F. Relation between the NCI common toxicity criteria and treatment related mortality in acute myeloid leukemia (AML). Submitted.
  3. Sandhu R, Lionberger JM, Othus M, Pagel JM, Shannon-Dorcy K, Hendrie P, Petersdorf S, Becker P, Appelbaum F, Estey EH.. Survival after Failure of Initial Therapy for Newly-Diagnosed or Relapsed/ Refractory AML at an Academic Center: Subsequent Clinical Trial vs. Not. Submitted.
  4. Orozco JJ, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Hylarides MD, Axtman A, Frayo SL, Green DJ, Gopal AK, O’Donnell P, Press OW, Pagel JM. Haploidentical Bone Marrow Transplantation using Anti-CD45 Radioimmunotherapy to Decrease Relapse in a Pre-clinical Murine Model. In preparation.
  5. Pagel JM, Spurgeon S, Awan F, Blum K, Lanasa MC, Flinn IW, Stromatt SC, Byrd JC, Gopal A. Phase 1 Study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and/or refractory NHL patients. In preparation.
  6. Newell L, Sandhu R, Becker P, Pagel JM, Hendrie P, Walter R, Petersdorf S, Shannon Dorcy K, Abkowitz J, Appelbaum F, Estey E. Probability of Eventual CR after Course 1 of Induction Therapy for Newly-Diagnosed AML as a Function of Speed of Neutrophil and Platelet Recovery. In preparation.
  7. Lionberger JM, Dean C, Wathen K, Scott B, Estey EH, Pagel JM. Innovative Phase I/II Statistical Design in Combination Chemotherapy that Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in de novo Adult AML. In preparation.

 Selected Abstracts:
  1. Orozco JJ, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Mawad R, Frayo SL, Hylarides MD, Green DJ, Gopal AK, O’Donnell P, Sandmaier BM, Press OW, and Pagel JM. Anti-CD45 Pretargeted Radioimmunotherapy Prior to Bone Marrow Transplantation without Total Body Irradiation Facilitates Engraftment from Haploidentical Donors and Prolongs Survival in a Disseminated Murine Leukemia Model. American Society of Blood and Marrow Transplantation, Poster presentation, 2013.
  2. Mawad R, Gooley TA, Rajendran JG, Fisher DR, Shield A, Orozco JJ, Hamlin DK, Wilbur DS, Hylarides MD, Gopal AK, Green DJ, Maloney DG, Sandmaier BM, Storb R, Appelbaum FR, Press OW, and Pagel JM. Pretargeted Radioimmunotherapy using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation. American Society of Blood and Marrow Transplantation, oral presentation, 2013.
  3. .Mawad R, O’Donnell P, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Deeg HJ, Shields A, Green DJ, Maloney DG, Sandmaier BM, Storb R, Appelbaum FR, Press OW, and Pagel JM. Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. Journal of the Am Soc of Hematology, poster presentation, 2012.
  4. Mawad R, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Deeg J, Shields A, Green DJ, Maloney DG, Sandmaier BM, Storb R, Appelbaum FR, Press OW, and Pagel JM. A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Journal of the Am Soc of Hematology, poster presentation, 2012.
  5. Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF, Darden DE, Nolan CE, Gressick LA, Yang J, Chyla BJ, Busman TA, Graham AM, Cerri E, Enschede SH, Humerickhouse RA, Seymour JF. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-to

The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey.Responses are measured on a 10 - point scale, with 10 being the best score. These scores are then translated to a 5 - point scale in order to display results in a 5 - star rating.Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments.

4.9 out of 5 (86 Ratings, 18 Comments)


I'm so happy to have Dr. Pagel as my doctor!

I actually believe I owe this part of my life to John Pagel, trust him 100%

It has been awhile since I saw Dr. Pagel, but i have complete confidence while in his care during my cancer remission.

Dr. Pagel, [...], and [...] are an excellent team. I'm fortunate to have them helping me.

Good eye - eye conversing sensitive to situation - helpful explanations of treatment options.

I think my doctor wants me to be happier than I show for my remission on cancer. I am very grateful but my boyfriend had to apologise for my being so full of questions based on fear of my cancer returning. I'm still in that state of noticing every little thing that isn't quite right with my health from before my cancer. I still have side-effects. My doctor was good at reffering me to a skin doctor. I asked about lymphedema and discovering the underlying cause of the auto immunity that led to my cancer. I guess I wanted more answers that he couldn't give. I'm wondering if I should see a rheumatologist or a naturopath. I probably will try to find one on my own rather than seek a referral to these.

Dr. Pagel explained the condition well & talked about the proposed treatment plan.

I plan to continue trusting Dr Pagel with my health.

If there was more consistency, I would more comfortable recommending.

I only had two appointments the first put me in [...] for seven days with Steven Johnson syndrome from a reaction to prescribed medication I can only say it was very bad.

wonderful Dr and Assistance. forturnate to be Dr Pagels patient.

Dr. Pagel is a top notch doctor!! Aside from being one of the best in his field, he is concerned for me as a whole and not in just treating my condition. This is a very refreshing and welcomed style of care experience. His example should be taught in med-school as the model to follow. Thanks, Doc!!

Dr. Pagel is outstanding in all areas.

Dr. Pagel is amazing, caring, thoughtful and considerate.

Superior care, utmost confidence in this provider. My insurance coverage kept me from continuing my cancer treatment with Dr. Pagel, which I regret. He kindly referred me to an excellent doctor in my health system, and consulted with the referred provider.

I simply can not imagine ANYONE better than DR. Pagel. I AM BLESSED!!

I would recommend Dr. Pagel to anyone looking for a doctor to treat blood disorders.

This was a visit to get a second opinion. I was diagnosed at [...]. Because of this visit I have switched to Swedish and Dr. Pagel. I mainly switched because of the kind staff, and the atmosphere of caring and professionalism at Swedish. Swedish is less crowded and I did not feel like I was in a rat-race there, like I did at [...]. I felt that everyone game me the time needed and I never felt rushed or overwhelmed or claustrophobic or worried or frightened like I have at other places.
Center for Blood Disorders and Stem Cell Transplantation
1221 Madison Street Floor 10
Seattle, WA 98104
Affiliated Facilities
Swedish Cherry Hill
Swedish First Hill
Swedish Edmonds